Obesity negates beneficial drug effects

Credit: CC0 Public Domain

Blocking CETP—a protein that shuttles cholesterol and triglycerides between lipoproteins such as HDL and LDL—has been shown to improve levels of the "good" cholesterol HDL. Outcomes from clinical trials of CETP inhibitors, however, have not demonstrated robust decreases in the risk of cardiovascular disease.

Because many participants in the CETP inhibitor trials were obese, Lin Zhu, MD, PhD, John Stafford, MD, PhD, and colleagues wondered if obesity affected the response to CETP inhibition. To explore this, they studied the effects of anacetrapib, a CETP inhibitor, in expressing CETP. They report that although CETP inhibition improved HDL levels in diet-induced obese mice, it increased liver inflammation and worsened insulin resistance compared to mice on a low-fat diet.

Their findings, reported in the journal Diabetes, suggest that the effects of CETP inhibition on HDL functionality are greatly influenced by high-fat diet-induced obesity and hyperlipidemia, possibly counterbalancing the potential benefits of CETP loss in reducing risk of .

Explore further

Raising 'good' cholesterol fails to protect against heart disease

More information: Lin Zhu et al. CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet, Diabetes (2018). DOI: 10.2337/db18-0474
Journal information: Diabetes

Citation: Obesity negates beneficial drug effects (2018, November 9) retrieved 21 January 2020 from https://medicalxpress.com/news/2018-11-obesity-negates-beneficial-drug-effects.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments